An Osaka University-led research team has recently published findings that provide a ray of hope for the millions of Parkinson’s disease (PD) sufferers worldwide. Although more common in those aged over sixty, PD can strike at any age, with an estimated prevalence of 41 per 100,000 people in their forties. And while not fatal in and of itself, the progressive neurodegeneration that is characteristic of PD can often cause secondary effects that lead to death.
The exact cause of PD is still a mystery, but researchers believe that both genetics and the environment are likely to play a part. Importantly though, all PD patients show a loss of dopaminergic neurons in the brain and increased levels of a protein called ?-synuclein, which accumulates in Lewy bodies. Lewy bodies are a pathological feature of both familial and sporadic forms of the disease, as well as some types of dementia.
In the study published this month in Scientific Reports, the team led by researchers from Osaka University’s Graduate School of Medicine focused on ?-synuclein as a target for a novel PD treatment.
“Although there are drugs that treat the symptoms associated with PD, there is no fundamental treatment to control the onset and progression of the disease,” explains lead author Takuya Uehara. “Therefore, we looked at ways to prevent the expression of ?-synuclein and effectively eliminate the physiological cause of PD.”
To do this, the researchers designed short fragments of DNA that are mirror images of sections of the ?-synuclein gene product. The constructs were stabilized by the addition of amido-bridging. The resulting fragments, called amido-bridged nucleic acid-modified antisense oligonucleotides (ASOs), bind to their matching mRNA sequence, preventing it from being translated into protein. After screening 50 different ASOs, the researchers settled on a 15-nucleotide sequence that decreased ?-synuclein mRNA levels by 81%.
“When we tested the ASO in a mouse model of PD, we found that it was delivered to the brain without the need for chemical carriers,” says co-lead author Chi-Jing Choong. “Further testing showed that the ASO effectively decreased ?-synuclein production in the mice and significantly reduced the severity of disease symptoms within 27 days of administration.”
Explains senior author of the study Hideki Mochizuki, “Our results showed that gene therapy using ?-synuclein-targeting ASOs is a promising strategy for the control and prevention of PD. We expect that in the future, this method will be used to not only successfully treat PD, but also dementia caused by ?-synuclein accumulation.”
Learn more: Stopping Parkinson’s disease before it starts
The Latest on: Parkinson’s disease
via Google News
The Latest on: Parkinson’s disease
- Global Chronic Kidney Disease Drugs Market Grow At A CAGR Of 4.1% During The Forecast Period 2020-2025on March 4, 2021 at 1:33 am
Global Chronic Kidney Disease Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025 [85 pages report] This market research report includes a detailed segmentation of the ...
- World Obesity Day: How to manage this complex yet deadly diseaseon March 3, 2021 at 11:54 pm
It’s no secret that the number of calories people eat and drink has a direct impact on their weight.However, even though people may know about the impact of food choices on our health, overweight and ...
- Get into the swing: Golf is better than tai chi for improving balance and mobility in people with Parkinson's diseaseon March 3, 2021 at 1:00 pm
Volunteers with Parkinson's in the US were asked to either practice their golf swing or take Tai Chi lessons for ten weeks and have their mobility tested before and after the session.
- Strongbridge Biopharma files new drug application with FDA for rare disease therapyon March 3, 2021 at 11:44 am
A Bucks County biopharm firm has filed an application seeking approval for its experimental therapy targeting the rare disease known as Cushing's syndrome.
- Parkinson's Foundation Releases Results of First-Ever Medical Cannabis and Parkinson's Disease Surveyon March 3, 2021 at 6:02 am
The Parkinson's Foundation today announced the results of the medical cannabis and Parkinson's disease (PD) survey. The survey, titled Weeding Through the Haze: A Survey on Cannabis Use Among People ...
- One coronavirus vaccine dose up to 80% effective at warding off severe disease in elderly after 14 days, study suggestson March 3, 2021 at 5:21 am
A single dose of a coronavirus vaccine is up to 80% effective at preventing complications severe enough to require hospitalisation among the elderly, research suggests. The UK has three approved ...
- Researchers identify drug target to fight Parkinson’s and Alzheimer’s diseaseon March 3, 2021 at 1:11 am
Neurodegenerative disorders such as Parkinson's and Alzheimer's disease are in the firing line after researchers identified an attractive therapeutic drug target.
- Brain's Metabolic Run-up to Dementia Directly Linked to Hypertension, Carotid Diseaseon March 2, 2021 at 1:34 pm
Hypoperfusion by PET imaging in brain regions linked to cognitive function were independently related to preclinical carotid disease and CV risk score, particularly the hypertension component.
- Time to ditch the sausages? Eating meat or poultry just three times a week can increase your risk of heart disease, pneumonia and diabetes, study warnson March 2, 2021 at 10:02 am
The research from Oxford University found that a meat-lover who eats 70 grams of meat - processed or unprocessed - more than a peer is at 15 per cent higher risk of heart disease.
- Researchers find effective combination of therapies for managing mitochondrial diseaseon March 2, 2021 at 9:47 am
Researchers from the Mitochondrial Medicine Frontier Program at Children's Hospital of Philadelphia (CHOP) have demonstrated how one combination of therapies may be beneficial for patients with ...
via Bing News